Novel therapeutic strategy for breast cancer: mammalian target of rapamycin inhibition

Bibliography

• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30
   PubMed Web of Science ®Google Scholar
• Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216(2):141-50
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
   PubMed Web of Science ®Google Scholar
• Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96
   PubMed Web of Science ®Google Scholar
• Silva J, Cavazos DA, Donzis E, et al. Akt-induced tamoxifen resistance is associated with altered FKHR regulation. Cancer Invest 2007;25(7):569-73
   PubMed Web of Science ®Google Scholar
• Park SS, Kim SW. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncol Rep 2007;18(1):139-43
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006;13(2):137-44
   PubMedGoogle Scholar
• Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37
   PubMed Web of Science ®Google Scholar
• Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005;24:7443-54
   PubMed Web of Science ®Google Scholar
• Gschwendt M. Protein kinase Cδ. Eur J Biochem 1999;259:555-64
   PubMedGoogle Scholar
• Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cδ. Biochem J 2004;384:449-59
   PubMed Web of Science ®Google Scholar
• Salh B, Marotta A, Matthewson C, et al. Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 1999;19:731-40
   PubMed Web of Science ®Google Scholar
• Mountzios G, Soria JC. Targeted therapy in oncology. New York: Informa Healthcare, 2007
   Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88
   PubMed Web of Science ®Google Scholar
• Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756-8
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62
   PubMed Web of Science ®Google Scholar
• Boulay A, Lane HA. The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res 2007;172:99-124
   PubMedGoogle Scholar
• Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-61
   PubMed Web of Science ®Google Scholar
• Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005;17:158-66
   PubMed Web of Science ®Google Scholar
• Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66(11):5549-54
   PubMed Web of Science ®Google Scholar
• Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Sokolosky ML, Lehmann BD, et al. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Adv Enzyme Regul 2008;48(1):113-35
   PubMedGoogle Scholar
• Steelman LS, Navolanic PM, Sokolosky ML, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008;27(29):4086-95
   PubMed Web of Science ®Google Scholar
• Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10(20):7031-42
   PubMed Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4(4):257-62
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30(2):193-204
   PubMed Web of Science ®Google Scholar
• Skotnicki JS, Leone CL, Smith AL, et al. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: The dentification of CCI-779. [abstract 477]. Clin Cancer Res 2001;7:3749S-50S
   Google Scholar
• Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8(3):249-58
   PubMed Web of Science ®Google Scholar
• Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001;7(6):1758-64
   PubMed Web of Science ®Google Scholar
• Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001;98(18):10314-9
   PubMed Web of Science ®Google Scholar
• Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo. [abstract 2000]. Proc Am Assoc Cancer Res 1999;40:301
   Google Scholar
• Sadler TM, Gavriil M, Annable T, et al. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer 2006;13(3):863-73
   PubMed Web of Science ®Google Scholar
• Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22(12):2336-47
   PubMed Web of Science ®Google Scholar
• Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23(23):5314-22
   PubMed Web of Science ®Google Scholar
• Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91(8):1420-4
   PubMed Web of Science ®Google Scholar
• deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004;10:8059-67
   PubMed Web of Science ®Google Scholar
• Peralba JM, deGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9(8):2887-92
   PubMed Web of Science ®Google Scholar
• Baselga J, Roché H, Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study. [abstract]. Breast Cancer Res Treat 2005;94(Suppl 1):1068
   Google Scholar
• Gligorov J, Azria D, Namer M, et al. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol 2007;64(2):115-28
   PubMed Web of Science ®Google Scholar
• Johnston SR, Martin LA, Leary A, et al. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 2007;106(1-5):180-6
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, et al. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann Oncol 2008;19(6):1097-109
   PubMed Web of Science ®Google Scholar
• Beuvink I, O'Reilly T, Zumstein S, et al. Antitumor activity of RAD001, an orally active rapamycin derivative. [abstract 1972]. Proc Am Assoc Cancer Res 2001;42(suppl):366
   Google Scholar
• O'Reilly T, Vaxelaire J, Muller M. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. [abstract 359]. Proc Am Assoc Cancer Res 2002;43(suppl):71
   Google Scholar
• Lane H, Tanaka C, Kovarik J, et al. Preclinical and clinical pharmacokinetic/ pharmacodynamic (PK/PD) modeling to help define an optimal biological dose for the oral mTOR inhibitor, RAD001, in oncology. [abstract 951]. Proc Am Soc Clin Oncol 2003;22(suppl):237
   Web of Science ®Google Scholar
• Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-61
   PubMed Web of Science ®Google Scholar
• Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11(14):5319-28
   PubMed Web of Science ®Google Scholar
• Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59
   PubMed Web of Science ®Google Scholar
• Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005;4:101-12
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007;67(6):2408-13
   PubMed Web of Science ®Google Scholar
• Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98(5):923-30
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19(10):2722-30
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13(19):5883-8
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588-95
   PubMed Web of Science ®Google Scholar
• Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44(1):84-91
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer. [abstract]. Breast Cancer Res Treat 2007;106(Suppl 1):2066
   Google Scholar
• Rivera V, Kreisberg J, Mita M, et al. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. [abstract 3033]. J Clin Oncol 2005;23(Suppl):200s
   Google Scholar
• Rivera VM, Berk L, Mita M, et al. Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials. [abstract 123]. Eur J Cancer 2004;2(Suppl 8):123
   Web of Science ®Google Scholar
• Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26(3):361-7
   PubMed Web of Science ®Google Scholar
• Mita MM, Britten CD, Poplin E, et al. Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J Clin Oncol 2008;26(suppl):3509
   Web of Science ®Google Scholar
• Rizzieri DA, Feldman E, DiPersio JF, et al. A phase 2 clinical trial of Deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14(9):2756-62
   PubMed Web of Science ®Google Scholar
• Figlin RA, Brown E, Armstrong AJ, et al. NCCN task force report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008;6(Suppl 5):S1-20; quiz S21-S22
   PubMedGoogle Scholar
• Xing H, Weng D, Chen G, et al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 2008;261:108-19
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Kimura Y, Oki E, et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006;118(2):284-9
   PubMed Web of Science ®Google Scholar
• Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005;95(1-5):155-65
   PubMed Web of Science ®Google Scholar
• Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276(13):9817-24
   PubMed Web of Science ®Google Scholar
• Scott PH, Brunn GJ, Kohn AD, et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA 1998;95:7772-7
   PubMed Web of Science ®Google Scholar
• Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001;98:136-41
   PubMed Web of Science ®Google Scholar
• Hutchinson J, Jin J, Cardiff RD, et al. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001;21:2203-12
   PubMed Web of Science ®Google Scholar
• Heinonen H, Nieminen A, Saarela M, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics 2008;9. In press
   PubMedGoogle Scholar
• Lee C, Dhillon J, Wang MY, et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 2008;68(21):8661-6
   PubMed Web of Science ®Google Scholar
• Chollet P, Abrial C, Tacca O, et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006;7(4):336-8
   PubMed Web of Science ®Google Scholar
• Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18(8):1323-8
   PubMed Web of Science ®Google Scholar
• Generali D, Fox SB, Brizzi MP. Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008;14(9):2673-80
   PubMed Web of Science ®Google Scholar
• Chau CH, Wang W, Figg WD. Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis. Cancer Biol Ther 2008;7(9):1386-7
   PubMedGoogle Scholar
• Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68(19):8022-30
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68(22):9221-30
   PubMed Web of Science ®Google Scholar